# Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.

> **NCT00481767** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 676 (actual)

## Conditions studied

- Human Papillomavirus (HPV) Infection

## Interventions

- **BIOLOGICAL:** Cervarix
- **DRUG:** Placebo Al(OH)3

## Key facts

- **NCT ID:** NCT00481767
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10-01
- **Primary completion:** 2010-02-25
- **Final completion:** 2010-07-26
- **Target enrollment:** 676 (ACTUAL)
- **Last updated:** 2020-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00481767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00481767, "Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00481767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*